BC
MLTX icon

Bulwark Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bulwark Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.85K Buy
+500
New +$8.17K ﹤0.01% 99

Other funds holding MLTX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BWM
BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Bulwark Capital's MLTX Position: Q3 2026 in Review

Bulwark Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 500 shares worth $5.85K. The stake represents ﹤0.01% of the portfolio and ranks #99 among its holdings.

9 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Bulwark Capital held 500 shares of MoonLake Immunotherapeutics worth $5.85K as of Q3 2026.
  • MoonLake Immunotherapeutics was a new Bulwark Capital position in Q3 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Bulwark Capital's portfolio in Q3 2026, its #99 holding.
  • 9 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Bulwark Capital's 13F filing for Q3 2026, filed 13 Oct 2026.